60 Validated Planets from K2 Campaigns 5-8

We present a uniform analysis of 155 candidates from the second year of NASA's $K2$ mission (Campaigns 5-8), yielding 60 statistically validated planets spanning a range of properties, with median values of $R_p$ = 2.5 $R_\oplus$, $P$ = 7.1 d, $T_\mathrm{eq}$ = 811 K, and $J$ = 11.3 mag. The sample includes 24 planets in 11 multi-planetary systems, as well as 18 false positives, and 77 remaining planet candidates. Of particular interest are 18 planets smaller than 2 $R_\oplus$, five orbiting stars brighter than $J$ = 10 mag, and a system of four small planets orbiting the solar-type star EPIC 212157262. We compute planetary transit parameters and false positive probabilities using a robust statistical framework and present a complete analysis incorporating the results of an intensive campaign of high resolution imaging and spectroscopic observations. This work brings the $K2$ yield to over 360 planets, and by extrapolation we expect that $K2$ will have discovered $\sim$600 planets before the expected depletion of its on-board fuel in late 2018.Comment: 33 pages, 13 figures, 5 tables, accepted for publication in A

Sunflowers, 1980

Cover title."This first report of results is a contribution of the Department of Agronomy, University of Missouri Agricultural Experiment Station, which reports on Research Projet 363"--P. 3

A Correlation Between Stellar Activity and Hot Jupiter Emission Spectra

We present evidence for a correlation between the observed properties of hot Jupiter emission spectra and the activity levels of the host stars measured using Ca II H & K emission lines. We find that planets with dayside emission spectra that are well-described by standard 1D atmosphere models with water in absorption (HD 189733, TrES-1, TrES-3, WASP-4) orbit chromospherically active stars, while planets with emission spectra that are consistent with the presence of a strong high-altitude temperature inversion and water in emission orbit quieter stars. We estimate that active G and K stars have Lyman alpha fluxes that are typically a factor of 4-7 times higher than quiet stars with analogous spectral types, and propose that the increased UV flux received by planets orbiting active stars destroys the compounds responsible for the formation of the observed temperature inversions. In this paper we also derive a model-independent method for differentiating between these two atmosphere types using the secondary eclipse depths measured in the 3.6 and 4.5 micron bands on the Spitzer Space Telescope, and argue that the observed correlation is independent of the inverted/non-inverted paradigm for classifying hot Jupiter atmospheres.Comment: 9 pages, 5 figures, accepted for publication in ApJ. The updated paper includes spectra for ten additional systems and a new section discussing the connection between chromospheric activity and UV flu

Emerging Leadership in Nonprofit Organizations: Myths, Meaning and Motivations

This report contributes to the understanding of, and conversation about, how to develop emerging leaders in the nonprofit sector. It provides recommendations for various stakeholders of the sector, including funders. A bibliography is included

Factors related to successful job reintegration of people with a lower limb amputation

Objective: To study demographically, amputation-, and employment-related factors that show a relationship to successful job reintegration of patients after lower limb amputation. Design: Cross-sectional study. Setting: University hospital. Patients: Subjects had an acquired unilateral major amputation of the lower limb at least 2 years before, were aged 18 to 60 years (mean, 46yr), and were living in the Netherlands. All 322 patients were working at the time of amputation and were recruited from orthopedic workshops. Intervention: Questionnaires sent to subjects to self-report (1) demographic and amputation information and (2) job characteristics and readjustment postamputation. Questionnaire sent to rehabilitation specialists to assess physical work load. Main Outcome Measures: Demographically related (age, gender); amputation-related (comorbidity; reason and level; problems with stump, pain, prosthesis use and problems, mobility, rehabilitation); and employment-related (education, physical workload) information about the success of job reintegration. Results: Job reintegration was successful in 79% and unsuccessful in 21% of the amputees. Age at the time of amputation, wearing comfort of the prosthesis, and education level were significant indicators of successful job reintegration. Subjects with physically demanding jobs who changed type of job before and after the amputation more often successfully returned to work than subjects who tried to stay at the same type of job. Conclusions: Older patients with a low education level and problems with the wearing comfort of the prosthesis are a population at risk who require special attention during the rehabilitation process in order to return to work. Lowering the physical workload by changing to another type of work enhances the chance of successful reintegration

Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer's disease: the MADE Phase II, three-arm RCT

Background: Minocycline is an anti-inflammatory drug and protects against the toxic effects of β-amyloid in vitro and in animal models of Alzheimer’s disease. To the best of our knowledge, no randomised placebo-controlled clinical trials in patients with Alzheimer’s disease looking at the efficacy and tolerability of minocycline have been carried out. Objectives: The trial investigated whether or not minocycline was superior to placebo in slowing down the rate of decline in cognitive and functional ability over 2 years. The safety and tolerability of minocycline were also assessed. Design: A Phase II, three-arm, randomised, double-blind, multicentre trial with a semifactorial design. Participants continued on trial treatment for up to 24 months. Setting: Patients were identified from memory services, both within the 32 participating NHS trusts and within the network of memory services supported by the Dementias and Neurodegenerative Diseases Research Network (also known as DeNDRoN). Participants: Patients with standardised Mini Mental State Examination scores of > 23 points and with Alzheimer’s disease assessed by the National Institute on Aging–Alzheimer’s Association’s criteria were identified from memory services. Intervention: Patients with mild Alzheimer’s disease were randomly allocated 1 : 1 : 1 to receive one of three treatments: arm 1 – 400 mg per day of minocycline; arm 2 – 200 mg per day of minocycline; or arm 3 – placebo. Patients continued treatment for 24 months. Participants, investigators and outcome assessors were blind to treatment allocation. Main outcome measures: Primary outcome measures were decline in standardised Mini Mental State Examination and Bristol Activities of Daily Living Scale scores of combined minocycline treatment arms versus placebo, as analysed by intention-to-treat repeated measures regression. Results: Between 23 May 2014 and 14 April 2016, 554 participants were randomised. Of the 544 eligible participants, the mean age was 74.3 years and the average standardised Mini Mental State Examination score was 26.4 points. A total of 252 serious adverse events were reported, with the most common categories being neuropsychiatric and cardiocirculatory. Significantly fewer participants completed treatment with 400 mg of minocycline [29% (53/184)] than 200 mg [62% (112/181)] or placebo [64% (114/179)] (p < 0.0001), mainly because of gastrointestinal symptoms (p = 0.0008), dermatological side effects (p = 0.02) and dizziness (p = 0.01). Assessment rates were also lower in the 400-mg treatment arm: 68% (119 of 174 expected) for standardised Mini Mental State Examination scores at 24 months, compared with 82% (144/176) for the 200-mg treatment arm and 84% (140/167) for the placebo arm. Decline in standardised Mini Mental State Examination scores over the 24-month study period in the combined minocycline arms was similar to that in the placebo arm (4.1- vs. 4.3-point reduction; p = 0.9), as was the decline in the 400- and 200-mg treatment arms (3.3 vs. 4.7 points; p = 0.08). Likewise, worsening of Bristol Activities of Daily Living Scale scores over 24 months was similar in all trial arms (5.7, 6.6 and 6.2 points in the 400-mg treatment arm, 200-mg treatment arm and placebo arm, respectively; a p-value of 0.57 for minocycline vs. placebo and a p-value of 0.77 for 400 vs. 200 mg of minocycline). Results were similar in different patient subgroups and in sensitivity analyses adjusting for missing data. Limitations: Potential limitations of the study include that biomarkers were not used to confirm the diagnosis of Alzheimer’s disease, as these and apolipoprotein E (APOE) genotyping are not routinely available within the NHS. Compliance was also worse than expected and differential follow-up rates were observed, with fewer assessments obtained for the 400-mg treatment arm than for the 200-mg treatment and placebo arms. Conclusions: Minocycline does not delay the progress of cognitive or functional impairment in people with mild Alzheimer’s disease over a 2-year period. Minocycline at a dose of 400 mg is poorly tolerated in this population. Future work: The Minocycline in mild Alzheimer’s DiseasE (MADE) study provides a framework for a streamlined trial design that can be usefully applied to test other disease-modifying therapies